DongBang Medical Co Ltd

DongBang Medical maintains a conservative capital structure with a debt-to-equity ratio of 0.27, indicating limited leverage. The company holds 12 billion KRW in cash and equivalents, but its long-term debt of 33.2 billion KRW results in a net cash position of -21.2 billion KRW, raising liquidity concerns. The current ratio of 2.12 suggests adequate short-term liquidity to cover obligations. Profitability metrics show a return on equity (ROE) of 9.52% and a return on assets (ROA) of 6.27%, both above the industry median for medical equipment firms. The operating margin of 15.12% (calculated from operating income of 17.17 billion KRW on revenue of 113.54 billion KRW) reflects strong cost control and pricing power. The company's revenue is split between two segments: Cosmetic Medical Devices and Oriental Medical Devices. The Cosmetic segment, which includes hyaluronic acid fillers and cannulas, likely accounts for the majority of revenue, though exact segmental revenue figures are not disclosed. Geographically, the firm is concentrated in South Korea, with no material international revenue reported. Outlook data indicates a positive revenue trajectory, with a 12.3% year-over-year growth in the most recent fiscal year. Analysts project continued growth, with a mean price target of 19,000 KRW and a strong-buy recommendation. However, capital expenditures of -14.72 billion KRW suggest a focus on cost optimization rather than expansion. Risk factors include liquidity constraints due to the net cash deficit and the potential for dilution if the company issues additional shares to fund operations or growth initiatives. The risk assessment flags net cash as negative after subtracting total debt, and while dilution is currently rated as low, the company's liquidity risk is classified as medium. Recent filings and transcripts do not highlight material events, but the company's focus on cosmetic and traditional medical devices positions it to benefit from growing demand in aesthetic and alternative medicine markets. No significant regulatory or operational risks were disclosed in the latest reports.